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Interassay Variability of Immunometric Methods for Thyrotropin in an External Quality
Assessment Survey: Evidence That Functional Sensitivity Is Not Always Adequate
for Clinical Decisions
A. Pilo,1 G. C. Zuccheffi,’ R. Malvano,2 A. Clerico,’ G. lervasi,’ and C. Slgnorini2
We investigated the ability of current immunometric meth-
odsfor thyrotropin (TSH; thyroid-stimulating hormone) to
distinguish between low-normal and subnormal hormone
concentrations by using the data from an external quality
assessment (EQA) survey in 1990. We computed the
interassay(between-run)precisionprofilesfrom results
from 101 laboratories,whichused the five mostpopular
kits in the survey;duringthe controlperiod (one year)
each laboratory assayed 4 EQA pools distributed (as
hidden replicates) in five occasions. The interassay CV
was relatively low (9-i 3%) for three poolsin the normal
TSH range (>0.8 milli-int. unitlL) but markedly higher
(30-40%, except for one more precise kit) in the subnor-
mal range (0.2 milli-int. unit/L). We calculated the effect of
the between-run variability on the diagnostic accuracy
(discrimination between normal and subnormal values)
for three representative TSH concentrations: 0.2,0.4, and
0.5 milli-int. unit/L (0.3 milli-int. unit/L was considered the
lower normal limit). The three concentrations were rea-
sonably discriminated (P s5%), and only one kit showed
a between-run CV <i8% at 0.2 milli-int. unitlL. For the
other four less-precise kits, only the higher TSH value (0.5
miili-int. unit/L) could be classified with an acceptable
diagnostic reliability. With the most precise kit, one can
distinguish two TSH concentrations in the 0.3-0.5 milli-int.
unit/L range that differ by at least 30%; with the other kits,
differences greater than 50-60% are needed for reliable
discrimination. Thus many laboratories fall to achieve the
functional sensitivity of a second-generation assay, even
if they use immunomettic methods. TSH assays with a
better interassay precision in the low concentration range
are needed.
AdditIonal Keyphrases: distinguishinglow-normal from below-
normal thyrotropin concentrations thyroid status
During the past five years, the traditional competitive
RIA methods for thyrotropin (thyroid-stimulating hor-
mone, TSH) determination have been increasingly re-
placed by the so-called ultrasensitive or supersensitive
immunometric assays (IMAs) based on noncompetitive
“two-site” technology.3 Almost all of these methods use
monoclonal antibodies to extract TSH from the serum
samples (solid-phase “capture” antibody) and to quan-
tify the bound analyte (“tracer” antibody). The label for
the tracer antibody may be either or a nonradioac-
tive molecule, e.g., enzymes, fluorescent dyes, and
chemiluminescent compounds.
Commercially available kits based on IMA technol-
ogy are generally presented as being -10-fold more
sensitive than the traditional competitive RIAs (detec-
tion limits of 0.1 milli-int. unit/L versus 0.6-LO milli-
int. unit/L, calculated either from within-run replicate
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Italy.2lnstitute of Chemistry, School of Medicine, University of
Brescia, Italy.
3Nonstandard abbreviations: TSH, thyrotropin (thyroid-stimu-
lating hormone); IMA, immunometric assay; EQA, external qual-
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measurements of the zero standard or from within-run
precision profiles). Because of this markedly increased
analytical sensitivity, these methods are claimed as
effective in discriminating between normal and subnor-
mal TSH concentrations. However, analytical sensitiv-
ity per se, although necessary, is not sufficient to assure
a reliable classification of the low TSH values. In fact,
clinical practice relies on determinations obtained in
different runs, and the continuity of clinical classifica-
tion is therefore entrusted primarily to the stability of
the assay over time (i.e., with respect to changes in
reagent characteristics or operators’ performance or
both). Thus, the functional performance of an assay is
more adequately assessed from the between-run preci-
sion in the range of clinical concern. In particular, it has
been proposed (1-3) that functional sensitivity, rather
than analytical sensitivity, be used to assess the ability
of a TSH assay in discriminating low hormone concen-
trations. The functional sensitivity is defined as the
TSH value at which interassay precision (CV) is 20%,
and only the methods that exhibit a functional sensitiv-
ity <0.2 milli-int. unitlL have been defined as second-
generation assays (3).
Following this line of reasoning, we used the data
collected during an external quality assessment (EQA)
for TSH assays (4, 5) to calculate the between-run
precision proffles of the participants that used the five
most popular kits in the survey. We evaluated func-
tional sensitivities and the ability to distinguish sup-
pressed TSH concentrations from TSH concentrations in
euthyroidism.
Materials and Methods
EQA scheme. The EQA scheme for TSH assay of the
CNR Institute for Clinical Physiology does not substan-
tially differ from similar programs (6, 7); participating
laboratories (-170), supplied monthly with three un-
known samples, are asked to perform the assay rou-
tinely and to return results indicating the method/kit
used. The data collected are computer-processed, and
periodic and end-of-period reports containing statistical
evaluations of results and estimates of the performance
of laboratories and kits are prepared and distributed to
participants. The approaches followed for the analysis of
EQA results and the reports for participants are de-
scribed in detail elsewhere (8,9).
Control material. Pools P042, P049, and P050, distrib-
uted in the EQA survey considered in this study, were
prepared by pooling normal sera. A low-concentration
pool (P048) was obtained by removing some of the TSH
content of normal sera by affinity chromatography with
CNBr-activated Sepharose 4B, previously conjugated
with a monoclonal anti-TSH antibody. Sodium thimero-
sal and neomycin sulfate were added as preservatives
and the samples were lyophilized.
Data analysis. We sent each of the four pools (P048,
P042, P049, P050) to participants in five different
monthly dispatches as unidentified replicate samples
during the 1990 EQA cycle. Thus, five determinations
carried out on the same control material were collected
over a period of at least seven months; consequently, the
interassay precision of each laboratory computed from
these results takes into account both the variations of
experimental conditions of the assays and the variations
in the batches of kit reagents. The interassay precision
of the kit was estimated as the median of the precisions
of all laboratories using that kit.
The total variability (variability of all results pro-
duced by the laboratories assaying the same pool on five
occasions) was broken down into the within-kit and
between-kit components by an analysis of variance
(ANOvA) technique previously described (5,10).
The effect of the between-run variability on the
diagnostic accuracy of the five kits considered was
evaluated as reported by Bayer (11). In detail, the rate
of false negatives was estimated from the tail of the
distribution of the determinations obtained for an
assigned subnormal TSH value [gaussianly distributed
with the SD computed from linear interpolation of the
four experimental points of the between-run precision
profile (see Figure 2)1 that lies beyond the lower limit of
the normal range (assumed as 0.3 milli-int. unitfL).
Conversely, we obtained the rate of false positives from
the tail of the distribution for a normal value that falls
below the lower limit of the normal range. The percent-
age of false results (either false negatives or false
positives) was read on the table of the standard normal
distribution (z score); the z-score value was computed
as z = (lower limit - x)ISD, where x is the chosen TSH
concentration (0.2 milli-int. unitfL being subnormal
and 0.4 and 0.5 milli-int. unit/L being low-normal
values), and SD is the between-run SD computed from
the precision profile corresponding to the concentration
x chosen (see Figure 3). The diagnostic accuracy is
considered acceptable when the number of false results
is <5%.
Following the same statistical approach, we used the
between-run precision profile to estimate the ability to
discriminate between two TSH values in the low con-
centration range. After a value x was assigned, the near-
est y value (y <x) distinguishable from x was determined
by setting the z score, z = (x - y)/(SD2 + SD2)#{176}5,equal
to 1.65. In other words, we ensured that the difference
(x - y) significantly differed from 0 at P <0.05. These
computations were carried out for three arbitrarily
assigned TSH values (0.3,0.4, and 0.5 milli-int. unitlL)
and for the five kits considered.
Results
The overall means of the determinations (-700 data
points) collected for each of the four pools analyzed
were 0.77, 1.08, and 1.39 milli-int. unitfL, respectively,
for the normal pools P042, P049, and P050, and 0.22
milli-int. unitiL for the subnormal pool P048. The
consensus means of the EQA samples derived from
each pool (assayed as five hidden replicates) showed a
variability (CV) of 4.2%, 3.1%, 1.9%, and 2.2% for pools
P048, P042, P049, and P050, respectively, demonstrat-
ing the stability of the control materials during the
EQA period.
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Fig. 1. Frequency dlstdbutlon of the EQA results obtained for pool
P048 (mean 0.22 mull-mt.unitJL,n = 642)
The overall agreement (or total CV) of the results in
the normal TSH range was relatively good in all cases
(28.3% for P042, 27.6% for P049, 18.6% for P050), but
was markedly worse for the low-concentration poo1 P048
(45.6%).
Figure 1 shows the histogram of all data collected for
the pool P048. Despite some right-sided skewness, the
distribution could be reasonably regarded as symmetri-
cal around the mean (0.22 milli-int. unitfL). However,
the spread of the data is so large that a consistent
fraction of both clearly subnormal and normal values
have been reported by participants for the same control
material.
This large spread cannot be attributed to systematic
differences between the means of different kits, as dem-
onstrated by the relevant data shown in Table 1 for the
five kits most frequently used in EQA (about 70% of
results). Consequently, the major cause of variability
should be the poor within-kit reproducibility. To quan-
tify the relative percentages that systematic between-
kit differences and the within-kit variability contribute
to the total variability, we performed an ANOVA of the
results from pools P048 and P050. The results (Figure 2)
indicate that, for the pool at higher TSH concentration
(P050), the total variability (CV 18.6%) is -70% attrib-
utable to the within-kit component, with the remaining
30% being due to systematic between-kit differences; on
the other hand, for the low-concentration pool P048, the
within-kit component accounts for as much as 95% of
the total variability of the data.
Clearly, total variability is enlarged to some extent by
the fact that results are produced in different laborato-
ries that use different kits. For this reason, we evalu-
ated the variability of single laboratories to estimate
whether their within-laboratory interassay precision
was adequate to allow the discrimination of TSH sub-
normal values from euthyroidism. Table 1 shows the
median and range of the interassay precision obtained
for the four EQA pools by the laboratories that used the
kit considered. These data are also presented in the
interassay precision profiles depicted in Figure 3, pro-
ifies that can be considered as representative of the
analytical performance of the different kits in the hands
of the average-quality laboratory.
For the kits from Serono Maiaclone (ARS), Boeh-
ringer Enzymun (BHN), Abbott (IMX), and Byk-
Sangtec (MAT), the interassay variability of the low-
concentration pool (0.22 milli-int. unitfL) was very high
(CV = 30-40%), implying that many users of these kits
fail to achieve a “second-generation” functional perfor-
mance; in particular, only 20-25% of the laboratories
that used ARS, IMX, and MAT kits (but none of the
BHN users) exhibited a second-generation performance.
On the other hand, the Behring immunoradiometric
assay (BEH) showed a CV of 17.6% for the low pool, and
75% of the users of this kit achieved a functional
sensitivity better than 0.2 milli-int. unitlL. The preci-
sion at higher concentrations (>0.8 milli-int. unitlL)
was relatively good (9-13%, on average) and adequate
for all five kits.
The effect of the interassay precision on the diagnostic
accuracy (discrimination between normal and subnor-
mal values) was calculated by assuming 0.3 milli-int.
unitlL as the lower normal limit. The diagnostic accu-
racy of the average-quality laboratory is reported in
Table 2 for three representative TSH concentrations,
one below the cut-off value and two in the lower part of
the normal range. The data indicate that the three
concentrations are reasonably discriminated (P 5%),
with only one kit (BEH) showing a between-run preci-
sion <18% at 0.2 milli-int. unitlL. For the other kits,
only the higher TSH concentration (0.5 milli-int. unitlL)
could be classified with an acceptable diagnostic reli-
ability.
Following the same statistical approach, for each kit
we computed the TSH concentration interval (around
the assumed cutoff of 0.3 milli-int. unit/L) in which the
diagnostic accuracy was worse than 95%. Because of the
poor between-run precision, the TSH values included
within this indeterminate interval cannot be classified
with a reasonable diagnostic accuracy (percent of false
results 5%). The concentrations in the interval from
-0.2-0.5 milli-int. unitlL could not be reliably classified
as normal or subnormal for four of five kits. In detail,
the indeterminate intervals were: 0.19-0.5 milli-int.
unit/L for ARS, 0.18-0.57 for BHN, 0.19-0.46 for IMX
and 0.19-0.51 for MAT; for the BEH kit, which shows
the best functional sensitivity, the indeterminate zone
was only 0.23-0.39 milhi-int. unit/L.
The effect of the interassay variability on the mini-
mum TSH decrease that can be significantly detected
was evaluated at three assigned concentrations (0.3,0.4,
and 0.5 milli-int. unitlL) for each of the five kits. This
discrimination is typically requested in monitoring pa-
tients receiving suppressive therapy with thyroxin.
With the kit that had the best between-run precision
(BEH), we could distinguish two TSH concentrations in
the range 0.3-05 milli-int. unitiL, if they differed by at
least 30%; with the other, less precise, kits, differences
of 50-60% or more were needed.
DiscussIon
The use of the within-run precision profile and of the
detection limit (both estimated from within-run repli-
P048 P042 P049 P050
No.01 TSH, TSH, TSH, TSH,
KItb labs mllll-lnt. unIt/I CV (range), % mUll-tat. unit/I CV (range), % mIlil-Int. unIt/I CV (rang,), % mIllI-Int. unlt/L CV (range), %
ARS 22 0.22 35.4 (7-66) 0.81 12.2 (5-50) 1.24 10.2(7-23) 1.53 6.7(3-19)
BEH 16 0.22 17.6 (4-41) 0.85 7.3 (3-19) 1.25 5.0(3-16) 1.57 5.4 (3-i 4)
BHN 28 0.20 42.5(21-84) 0.85 18.6(11-36) 1.11 9.8(6-37) 1.40 9.2(5-21)
IMXC 16 0.21 32.8 (7-64) 0.68 12.0 (5-31) 0.93 7.3(3-16) 1.19 7.4(3-22)
MAT 19 0.24 33.4(17-58) 0.80 15.9 (7-28) 1.11 12.5(6-37) 1.39 14.6(4-28)
The Interassay vanabllity is the median of the interassay CVsobtainedby the laboratories; the range of CVsis also reported.
b abbreviations: ARS, SeronoMaiacloneimmunoradiometricassay (Serono Labs., Milan, italy); BEH, Behring immunoradiometric assay (Behrlngwerke,
Marburg, FAG); BHN, Boehrlnger Enzymumtest (Boehiinger-Mannhelm.Mannhelm, FAG); MX, Abbott Mx system (Abbott Labs., Abbott Park, IL); MAT,
Byk-Sangtec immunoradiometric assay (Byk-Sangtee Diagnoetica. Dletzebbach, FAG).
#{176}data produced with aversionof the IMXkitthatwasavallthleln Italydurlng 1990. InJanuary 1991 this kftwas replacedwith anewverslon, “IMX
hTSHultrasensitive,” for which the manufacturer reports much better precision In the low-concentration range.
45.’
44.3
Totalvalablilty
#{149}Vithtn-ldt viriabtitty
o B.tw..n-kft virlability
ARS
0.2 36.2 0.072
0.4 28.3 0.11
0.5 24.4 0.12
655 55 66% 32%
P048 P050
1.38
-0.88
-1.64
BEH
0.2
0.4
0.5
8.4 (FN)
18.9(FP)
5.0 (FP)C
17.9 0.036
14.7 0.059
13.0 0.065
BHN
0.2
2.79
-1.71
-3.07
0.3 (FN)C
4.5 (FP)
<0.1 (FP)#{176}
50
40
30
42.5 0.085
0.4 35.2 0.14
0.5 31.5 0.16
1.18
-0.71
-1.27
IMX
0.2
0.4
0.5
11.9(FN)
24.2(FP)
10.2(FP)
50
K 40
>
Li 30
.0 20
t
0
FIg. 2. Breakdown of the total variability observed for EQA pools
P048 and P050 showing the between- and within-kitcomponents
CV% Is Indicated over the bars; the percent contribution of the two compo-
nents to the total variability is reported under the bars
K
>
U
Fig. 3. Between-run precision profiles of the five kits considered in
thisstudy
Ordinate: median of CV achieved by the laboratories; abscissa: consensus
means of the four pools; the profiles are calculated by linear Interpolation.
Functional sensitivity can be read as the TSH concentration corresponding to
the intersection of the precision profile with the broken line indicating 20%
between.run CV. For kit codes, see footnote to Table 1
cates) to evaluate a kit’s analytical performance in-
volves some risk of extrapolating to overall routine
operation a judgment derived from a merely episodic
observation. To prevent this risk, several investigators
have proposed and adopted the use of between-run
assessment (1-3, 12). This approach to the analysis of
33.2 0.066
24.4 0.10
20.0 0.10
MAT
1.50
-1.02
-2.00
6.7 (FN)
15.4 (FP)
2.3 (FP)#{176}
02 34.7 0.069
0.4 28.4 0.11
0.5 25.3 0.13
Table 2. Effect of Interassay Variability on DiagnostIc
Accuracy
TSH,x TSHSD, %Fals.
mIIIl-Int. unIt/I. CV, % mllIHnt. unlt/L (0.3 - s)/SDa rssultsb
#{149}Forcomputing the z score, 0.3 mull-mt. unit/I was assumed as the tower
limitof normal range.
b FN, false negative; FP, false positive.
C Diagnostic accuracy better than 95% (false results <5%) Is Indicated.
For kit codes, see footnote to Table 1.
data collected from EQA programs looks most effective:
the between-run precision relative to the same EQA
samples assayed in successive occasions allows, for each
individual method, consistent information to be ob-
tained not only based on a hong-term evaluation but also
involving a large number of laboratories. The state-of-
the-art performance, as actually emerging from routine
conditions, is thus evidenced.
We tried to evaluate the implications of the observed
between-run variability for clinical practice. In fact,
clinicians make their decisions on the basis of measure-
ments that are produced by the same laboratory on
different occasions and are therefore affected by the
same variability as observed in the multicenter trials.
Two typical situations were considered: classification of
1.44
-0.88
-1.58
7.5 (FN)
18.9(FP)
5.7 (FP)
0 0.5 1 1.5 2
TSH,, mW/I
Table 1. Means and Interassay Variabllltr Observed for EQA Pools Assayed with Five Kits
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a patient with respect to the lower limit of the normal
range, and assessment of variations of TSH concentra-
tion in patients taking thyroid-hormone-suppressive
therapy.
Analysis of the EQA results demonstrates that the
between-run precision in the low concentration range is
not generally adequate to ensure a discrimination be-
tween subnormal values and euthyroid values, even
when immunometric kits are adopted. In fact, with only
one of the five kits considered (i.e., BEH) did the major-
ity of the users (75%) attain a functional sensitivity
(<0.2 milli-int. unit/L) sufficient to meet this clinical
purpose; only 25% or fewer of the participants achieved
second-generation performance with the other kits.
Note that we used a single cutoff value (0.3 milli-int.
unitlL) to estimate the diagnostic accuracy (Table 2),
despite the large differences indicated by kit manufac-
turers for the lower normal limit (0.10-0.43 milli-int.
unitfL). Changing the cutoff value, however, although
modifying the rates of false positive and false negative
results, affects only niinim11y the overall width of the
indeterminate zone.
The lack of discrimination observed for these kits does
not affect the classification of overt hyperthyroidism, for
which the immunometric assays were developed. In-
stead, their still insufficient between-run precision
makes it difficult to distinguish among two TSH mea-
surements in the lower range and hence to evaluate
over time the effects of thyroid-hormone therapy (13).
These conclusions obviously refer to the laboratory of
average quality, with the understanding that better-
performing laboratories can fully discriminate, even
when using less-precise kits, and that some users of the
more precise kits cannot achieve these diagnostic goals.
In any case, our findings depict a much more pessimistic
situation than that emerging from the sensitivity and
precision data provided with kit instructions and based
on the most favorable experimental conditions. More-
over, our conclusions on the clinical performances of the
kits take into account only the between-run variability
estimated from replicates of control materials; other
factors, e.g., the presence of interfering substances in
patients’ samples, can further deteriorate diagnostic
accuracy.
A new class of kits, having enhanced precision at
lower concentrations-either from greater sensitivity or
from improved stability over time of the reagents and
experimental conditions-should be developed to re-
place the second-generation methods currently used in
the laboratory. The first third-generation TSH immu-
noassay with a functional sensitivity of about 0.02
milli-int. unitlL (10-fold greater than that of the second-
generation IMAs) has been recently described (12-14)
and appears to be a promising tool to refine the assess-
ment of the thyroid status.
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